Sashi Nadanaciva

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

Yi‐Long Wu, Ying Cheng, Xiangdong Zhou et al. · The Lancet Oncology · 2017 · 1.2K citations

Medicine, Oncology, Pharmacology +12

Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro

James A. Dykens, Joseph Jamieson, Lisa D. Marroquin et al. · Toxicology and Applied Pharmacology · 2008 · 222 citations

Life Sciences, Biochemistry, Pharmacology +17

Effect of the Multitargeted Tyrosine Kinase Inhibitors Imatinib, Dasatinib, Sunitinib, and Sorafenib on Mitochondrial Function in Isolated Rat Heart Mitochondria and H9c2 Cells

Yvonne Will, James A. Dykens, Sashi Nadanaciva et al. · Toxicological Sciences · 2008 · 215 citations

Life Sciences, Oncology, Pharmacology +17

A high content screening assay for identifying lysosomotropic compounds

Sashi Nadanaciva, Shuyan Lu, David F. Gebhard et al. · Toxicology in Vitro · 2010 · 205 citations

Life Sciences, Biochemistry, Molecular Biology +11

In Vitro Assessment of Mitochondrial Dysfunction and Cytotoxicity of Nefazodone, Trazodone, and Buspirone

James A. Dykens, Joseph Jamieson, Lisa D. Marroquin et al. · Toxicological Sciences · 2008 · 193 citations · Full text

Pharmacy, Pharmacology, Toxicology +17